HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that it was awarded two Bronze Telly Awards as part of the 2011 32nd Annual Telly Awards. Acorda received a Bronze Telly for its “Southern California Challenge Walk MS” documentary as well as a Bronze Telly in the public relations category for its “Employee Profiles" videos featured on the Company’s corporate website www.acorda.com. Acorda collaborated with biomed digital marketing agency StudioPMG to create both the documentary and the web-based video content.
“We are delighted to be recognized by the Telly Awards for both our MS documentary and the employee profiles on Acorda’s web site,” said Ron Cohen, President and Chief Executive Officer of Acorda Therapeutics. “Both initiatives reflect Acorda’s focus on people; those who are living with the many challenges of neurological diseases such as MS and those at Acorda who are committed to developing new therapies to help meet those challenges.”
The documentary – “Southern California Challenge Walk MS” – followed Team OptiMiStic, a group of seven women, five of whom have multiple sclerosis (MS), as they walked 50 miles in three days during the 2009 MS Challenge Walk, following their progress from Carlsbad to San Diego, California. The documentary can be viewed on the “I Walk Because” website at www.iwalkbecause.org.
Acorda’s “Employee Profiles" campaign is a series of videos featuring employees who discuss their experiences at the Acorda and how their work contributes to the Company’s mission, principles and values. The videos can be viewed at www.acorda.com/About/OurEmployees.aspx.
The Telly Awards honor the very best local, regional, and cable television commercials and programs, as well as the finest video and film productions, and work created for the Web. The 32nd Annual Telly Awards received over 11,000 entries from all 50 states and 5 continents. For a list of all the 2011 winners, visit www.tellyawards.com.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. The Company is commercializing and marketing AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the United States. AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS); this was demonstrated by an improvement in walking speed. AMPYRA was developed using Elan’s Matrix Drug Absorption System (MXDAS®) technology and is manufactured by Elan based on a supply agreement with Acorda.
Acorda also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Ampyra in the United States and to successfully market Zanaflex Capsules; third party payors (including governmental agencies) may not reimburse for the use of Ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of Ampyra outside of the United States and our dependence on our collaboration partner Biogen Idec in connection therewith; competition; failure to protect Acorda Therapeutics' intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; the ability to obtain additional financing to support Acorda Therapeutics' operations; and, unfavorable results from our preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.